Merck Sharp & Dohme LLC

NCT07431866

Phase 1Completed41 people25 Feb 2026clinicaltrials.gov

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

CollaboratorPhase 2/3Recruiting750 people26 Jan 2026clinicaltrials.gov

NCT07300280

Phase 1Active, not recruiting60 people23 Dec 2025clinicaltrials.gov

NCT07222098

Phase 1Completed16 people29 Oct 2025clinicaltrials.gov

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Phase 3Recruiting1,023 people14 Oct 2025clinicaltrials.gov

NCT07216482

Phase 3Active, not recruiting996 people14 Oct 2025clinicaltrials.gov

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Phase 3Recruiting675 people24 Sept 2025clinicaltrials.gov

NCT07121959

Phase 1Completed14 people14 Aug 2025clinicaltrials.gov

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

Phase 2Recruiting250 people20 May 2025clinicaltrials.gov

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Phase 3Recruiting2,400 people13 May 2025clinicaltrials.gov

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Phase 3Recruiting1,123 people1 May 2025clinicaltrials.gov

NCT06890884

Phase 2Recruiting594 people24 Mar 2025clinicaltrials.gov

NCT06829199

Phase 2Withdrawn0 people17 Feb 2025clinicaltrials.gov

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Phase 3Recruiting770 people13 Feb 2025clinicaltrials.gov

NCT06799494

CollaboratorPhase 4Recruiting100 people29 Jan 2025clinicaltrials.gov

NCT06797635

Phase 2Recruiting372 people28 Jan 2025clinicaltrials.gov

NCT06788912

Phase 2Active, not recruiting60 people23 Jan 2025clinicaltrials.gov

NCT06772792

Phase 1Completed36 people14 Jan 2025clinicaltrials.gov

NCT06772779

Phase 1Completed36 people14 Jan 2025clinicaltrials.gov

NCT06745882

CollaboratorPhase 2Recruiting318 people20 Dec 2024clinicaltrials.gov